Ontology highlight
ABSTRACT:
PROVIDER: PRJNA963069 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR24350400_1.fastq.gz | Fastqsanger.gz | |||
| SRR24350400_2.fastq.gz | Fastqsanger.gz | |||
| SRR24350401_1.fastq.gz | Fastqsanger.gz | |||
| SRR24350401_2.fastq.gz | Fastqsanger.gz | |||
| SRR24350402_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 63 |
Similar Datasets
Project description:We performed RNA-seq analysis on exosomes derived from the clinical specimens of healthy control (HC), active tuberculosis (ATB) and latent tuberculosis infection (LTBI) individuals. Our results revealed the distinguished gene expression panels and patterns of the exosomes for the LTBI and ATB patients: We identified many up-regulated and down-regulated differentially expressed genes (DEGs) in the LTBI and ATB samples, and further screened the top-20 DEGs, which might provide a clue to differentiate HC, LTBI and ATB; We classified all the DEGs into six expression patterns, screened the top-20 genes in each pattern, and mainly focused on those highly expressed in LTBI and ATB; A lot of Mtb genes were only expressed and enriched in the exosomes of LTBI patients; Pathway and functional analysis further indicated the gradually increased deteriorated healthy signals in LTBI and ATB samples, including down-regulated signaling pathways/immune response, and up-regulated apoptosis/necrosis. Our findings not only add new data to tuberculosis clinical studies, but also facilitate the development of potential targets for the diagnosis, prevention and treatment of tuberculosis.
2017-08-11 | GSE94907 | GEO
Project description:72 candidate biomarkers evaluated for TB diagnosis using mRNA purified from whole blood of Active TB patients recruited in the UK and India, LTB and two groups of controls from the UK (i) from a low incidence region and (ii) individuals variably domiciled in the UK and India. Tuberculosis (TB) remains a major global threat and diagnosis of active TB ((ATB) both extra-pulmonary (EPTB) and pulmonary (PTB)) and latent TB (LTBI) remains challenging, particularly in high-burden countries which still rely heavily on conventional methods. Although molecular diagnostic methods are available, e.g., Cepheid GeneXpert, they are not universally available in all high TB burden countries. There is intense focus on immune biomarkers for use in TB diagnosis, which could provide alternative low-cost, rapid diagnostic solutions. In our previous gene expression studies, we identified peripheral blood leukocyte (PBL) mRNA biomarkers in a non-human primate TB aerosol-challenge model. Here, we describe a study to further validate select mRNA biomarkers from this prior study in new cohorts of patients and controls, as a prerequisite for further development. PBL mRNA was purified from ATB patients recruited in the UK and India, LTBI and two groups of controls from the UK (i) a low TB incidence region (CNTRLA) and (ii) individuals variably-domiciled in the UK and Asia ((CNTRLB), the latter TB high incidence regions). Seventy-two mRNA biomarker gene targets were analyzed by qPCR using the Roche Lightcycler 480 qPCR platform and data analyzed using GeneSpring™ 14.9 bioinformatics software. Differential expression of fifty-three biomarkers was confirmed between MTB infected, LTBI groups and controls, seventeen of which were significant using analysis of variance (ANOVA): CALCOCO2, CD52, GBP1, GBP2, GBP5, HLA-B, IFIT3, IFITM3, IRF1, LOC400759 (GBP1P1), NCF1C, PF4V1, SAMD9L, S100A11, TAF10, TAPBP, and TRIM25. These were analyzed using receiver operating characteristic (ROC) curve analysis. Single biomarkers and biomarker combinations were further assessed using simple arithmetic algorithms. Minimal combination biomarker panels were delineated for primary diagnosis of ATB (both PTB and EPTB), LTBI and identifying LTBI individuals at high risk of progression which showed good performance characteristics. These were assessed for suitability for progression against the standards for new Tuberculosis diagnostic tests delineated in the published World Health Organization (WHO) technology product profiles (TPPs)
2021-03-05 | GSE168247 | GEO
Project description:Transcriptome sequencing of human hepatocellular carcinoma
2025-01-24 | E-GEOD-33294 | ExpressionAtlas
Project description:Whole transcriptome sequencing of mouse regulatory T cells with and without Mef2d, Mef2c, HDAC1, HDAC2 or Dyrk1 deletion
2020-04-27 | E-GEOD-139480 | ExpressionAtlas
Project description:The human skeletal muscle transcriptome assessed with RNA sequencing
2025-01-21 | E-GEOD-58608 | ExpressionAtlas
Project description:Whole transcriptome profiling of the steady state and Hh-treated (8 hrs) Alpk1+/- (heterozygous) and Alpk1-/- (knockout) BMDMs using RNA-Sequencing approach
2018-09-17 | E-MTAB-7076 | ExpressionAtlas
Project description:Transcription profiling by high throughput sequencing of soybean transcriptome data
2019-05-15 | E-MTAB-4270 | ExpressionAtlas
Project description:Transcriptome sequencing of Foxtail millet Setaria italica for different tissues
2019-05-15 | E-GEOD-36391 | ExpressionAtlas
Project description:Whole transcriptome profiling of Esophageal adenocarcinoma and Barrett's
2025-01-23 | E-MTAB-4054 | ExpressionAtlas
Project description:RNA-sequencing of Sorghum tissues at different developmental stages (comparative transcriptome study)
2020-07-20 | E-MTAB-5956 | ExpressionAtlas